TAPT1

Across TCGA pan-cancer cohorts, TAPT1 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of TAPT1’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where TAPT1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types TAPT1 is over-expressed in tumor, although a few such as LSCC and HNSC show the opposite, repressed pattern.

LSCC, HNSC, and COAD are the cancer types where TAPT1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TAPT1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	II,III,IV	−0.716	<.001	9	view →
HNSC	Male	III,IV	−0.289	<.001	8	view →
COAD	All	All	−0.407	<.001	7	view →
CCRCC	All	All	−0.243	<.001	6	view →
PDAC	Male	All	−0.640	<.001	5	view →
LUAD	Male	All	−0.140	.023	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

TAPT1–LSCC

Open the LSCC breakdown →